Gállego Pérez-Larraya Jaime, Delattre Jean-Yves
Department of Neurology, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain; Service de Neurologie 2, Division Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Paris, France; CNRS, UMR 7225, INSERM, Paris, France.
Department of Neurology, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain; Service de Neurologie 2, Division Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie, Paris, France; CNRS, UMR 7225, INSERM, Paris, France
Oncologist. 2014 Dec;19(12):1258-67. doi: 10.1634/theoncologist.2014-0170. Epub 2014 Oct 23.
The current progressive aging of the population is resulting in a continuous increase in the incidence of gliomas in elderly people, especially the most frequent subtype, glioblastoma (GBM). This sociohealth shift, known as the "silver tsunami," has prompted the neuro-oncology community to investigate the role of specific antitumor treatments, such as surgery, radiotherapy, chemotherapy, and other targeted therapies, for these traditionally undertreated patients. Advanced age, a widely recognized poor prognostic factor in both low-grade glioma (LGG) and high-grade glioma patients, should no longer be the sole reason for excluding such older patients from receiving etiologic treatments. Far from it, results from recent prospective trials conducted on elderly patients with GBM demonstrate that active management of these patients can have a positive impact on survival without impairing either cognition or quality of life. Although prospective studies specifically addressing the management of grade 2 and 3 gliomas are lacking and thus needed, the aforementioned tendency toward acknowledging a therapeutic benefit for GBM patients might also apply to the treatment of patients with LGG and anaplastic gliomas. In order to optimize such etiologic treatment in conjunction with symptomatic management, neuro-oncology multidisciplinary boards must individually consider important features such as resectability of the tumor, functional and cognitive status, associated comorbidities, and social support.
当前人口的持续老龄化导致老年人中胶质瘤的发病率不断上升,尤其是最常见的亚型胶质母细胞瘤(GBM)。这种被称为“银色海啸”的社会健康转变促使神经肿瘤学界研究特定抗肿瘤治疗方法,如手术、放疗、化疗和其他靶向治疗,对这些传统上治疗不足的患者的作用。高龄是低级别胶质瘤(LGG)和高级别胶质瘤患者中广泛认可的不良预后因素,不应再成为将这些老年患者排除在病因治疗之外的唯一理由。恰恰相反,最近对老年GBM患者进行的前瞻性试验结果表明,对这些患者进行积极管理可对生存产生积极影响,而不会损害认知或生活质量。尽管缺乏专门针对2级和3级胶质瘤管理的前瞻性研究,因此需要进行此类研究,但上述承认GBM患者有治疗益处的趋势也可能适用于LGG和间变性胶质瘤患者的治疗。为了结合对症治疗优化此类病因治疗,神经肿瘤多学科委员会必须分别考虑肿瘤的可切除性、功能和认知状态、相关合并症以及社会支持等重要特征。